Overview
PEPS ranks this pair inside the Top 300 market-cap universe. That means Injective and BTW are liquid enough for an indexable comparison, with metrics refreshed on the hourly coin pipeline.
Quick winners
Full comparison
| Metric | INJ | BTW |
|---|---|---|
| Price | $5.15 | $1,880.52 |
| Market Cap | $490.41M | $178.58M |
| FDV | — | — |
| Volume 24h | $2.50M | $19.71M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 98.00 | 172.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | BTW |
|---|---|---|
| 1H | — | — |
| 24H | +5.19% | -27.50% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | BTW |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 63.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Indicator stacks for INJ/BTW currently lean on separate regimes: neutral versus bearish. Treat MACD and RSI as context, not as standalone entry triggers.
Fundamentals
| Metric | INJ | BTW |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
BTW
Pros and cons
Pros of Injective
- INJ often anchors narratives that attract sustained media and analyst coverage.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
Cons of Injective
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
Pros of BTW
- If technical momentum aligns, BTW may outperform on medium-term windows.
- BTW can offer higher relative beta when market attention rotates toward its niche.
- Active volume bursts on BTW sometimes precede sharper tactical moves.
Cons of BTW
- Relative underperformance versus Injective can persist through entire market regimes.
- Higher volatility on BTW cuts both ways and demands stricter risk limits.
- Trend failures on BTW often travel faster than on more established assets.
Which looks stronger right now?
Data currently points to a probabilistic edge for Injective on size and BTW on activity. Neither reading guarantees future returns.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $490.41M and rank #98; BTW shows $178.58M and #172. Where liquidity and flow matter, watch BTW. Where durability matters, watch Injective. AI composite scores (48.70/58.40) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or BTW?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or BTW?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and BTW.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. BTW currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.